{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Idhifa"},{"type":"Synonym","name":"enasidenib methanesulfonate"},{"type":"Synonym","name":"AG-221 mesylate"},{"type":"ChemicalStructureName","name":"2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, methanesulfonate (1:1)"},{"type":"ChemicalStructureName","name":"2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5- triazin-2-yl)amino]propan-2-ol methanesulfonate"},{"type":"CodeName","name":"CC-90007"}],"definition":{"html":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","text":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/enasidenibmesylate","text":"Enasidenib Mesylate"},"nciConceptId":"C137825","nciConceptName":"Enasidenib Mesylate","termId":752247,"name":"enasidenib mesylate","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"enasidenib-mesylate"}],"links":null}